MAIN ARTICLE
When a biomarker moves but outcomes do not
Pelacarsen uses an antisense approach to reduce production of apolipoprotein(a), an essential component of Lp(a). Earlier research demonstrated reductions approaching 80%. In the large Lp(a)HORIZON trial, however, a striking laboratory change did not produce a statistically significant improvement in its combined endpoint: cardiovascular death, nonfatal heart attack, nonfatal stroke and urgent coronary revascularization.
That distinction is fundamental to drug development. Changing a risk-related biomarker is not the same as proving that patients experience fewer serious events or live longer. Novartis disclosed the topline failure in September, but detailed numbers are needed to determine whether the result was narrowly positive, neutral, or suggested any unfavorable trends.
What doctors need to see next
The most revealing results may lie beneath the headline composite. Cardiologists want separate figures for heart attack and procedures to restore blood flow, since Lp(a)’s relationship with stroke is less straightforward than its association with coronary disease.

















